Drug
Hmpl 760
Hmpl 760: highest development phase Phase 3, developed by Hutchmed. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hutchmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| HMPL-760 NCT07409428 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| HMPL-760 NCT05176691 | Phase 1 | CLL/SLL |
| HMPL-760 NCT07643272 | Phase 1 |
Latest
Follow Hmpl 760 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.